TIMP2 Protein Levels and Gene Variants Trace Ageing and Neurodegeneration in Parkinson’s Disease

A single protein long suspected of linking the ageing brain to neurodegenerative disease is stepping into the spotlight. In a new study published in GeroScience, researchers from the University of Tübingen and the NMI Natural and Medical Sciences Institute report that levels of tissue inhibitor of metalloproteinase-2, or TIMP2, in cerebrospinal fluid rise with age and track markers of neurodegeneration in people with Parkinson’s disease, while specific genetic variants within the TIMP2 gene appear to influence cognitive and motor trajectories. The findings position TIMP2 as a window into the ageing-related biology that shapes how Parkinson’s disease unfolds, rather than a disease-specific signature on its own.

TIMP2 belongs to a family of endogenous inhibitors that restrain matrix metalloproteinases, a group of enzymes that remodel the extracellular matrix, the molecular scaffolding that surrounds and supports cells throughout the body. In the brain, this remodelling machinery is far more than passive infrastructure. It governs synaptic plasticity, the migration and repair of cells, inflammatory responses, and the clearance of protein aggregates. When the balance between metalloproteinases and their inhibitors tips, the consequences can include blood-brain barrier disruption, aberrant synaptic pruning, and the deposition of misfolded proteins such as amyloid-beta and alpha-synuclein, both central suspects in neurodegenerative disease.

TIMP2 has an especially intriguing pedigree. Earlier work by a different research group showed that delivering TIMP2-rich plasma from human umbilical cord blood into aged mice revitalised hippocampal function, suggesting the protein carries rejuvenating signals. Subsequent studies demonstrated that neuronal TIMP2 regulates hippocampus-dependent plasticity and extracellular matrix complexity, and that the protein declines with age. Conversely, postmortem analyses of brain tissue from Parkinson’s disease patients have documented altered expression of matrix metalloproteinases and their inhibitors, hinting that the remodelling system is disturbed in the disorder. What remained unclear was whether TIMP2 measurable in living patients reflects Parkinson’s disease processes, ageing, or both, and whether genetic variation in TIMP2 shapes clinical outcomes.

To address these questions, Milan Zimmermann, Kathrin Brockmann, Benjamin Roeben and colleagues measured TIMP2 concentrations in cerebrospinal fluid from 480 patients with Parkinson’s disease, 67 patients with dementia with Lewy bodies and 16 control participants. Dementia with Lewy bodies was included because it sits on a clinical continuum with Parkinson’s disease, sharing the aggregation of alpha-synuclein while differing in the timing and prominence of cognitive decline. The team also stratified patients according to their status in the GBA1 gene, mutations in which are among the most common and best characterised genetic risk factors for Parkinson’s disease and are known to accelerate cognitive deterioration and influence alpha-synuclein profiles in cerebrospinal fluid.

The study was designed to interrogate TIMP2 from two complementary angles. Cross-sectional analyses compared TIMP2 concentrations with clinical scales measuring cognition, motor function and depression, and with established cerebrospinal fluid biomarkers including beta-amyloid 1-42, total tau, phosphorylated tau, neurofilament light chain and alpha-synuclein. Longitudinal analyses then followed patients over time, grouping them by tertiles of TIMP2 concentration and by selected single nucleotide polymorphisms within the TIMP2 gene, to determine whether the protein or its genetic variants predicted the onset of cognitive impairment or the pace of motor decline.

The cross-sectional results were telling. Cerebrospinal fluid TIMP2 levels rose with age and correlated with markers of neurodegeneration, converging on the idea that the protein tracks the degenerative state of the nervous system. Sex differences emerged as well: male Parkinson’s disease patients showed higher TIMP2 levels than their female counterparts, and female dementia with Lewy bodies patients carrying GBA1 mutations exhibited elevated TIMP2 compared with controls. Sex-related differences in matrix metalloproteinase biology are increasingly recognised across cardiovascular and neurological disease, and these data suggest they extend to the TIMP2 axis in synucleinopathies.

Longitudinally, TIMP2 concentrations did not significantly predict whether or when patients developed cognitive impairment, tempering the hope that the protein alone could serve as a straightforward prognostic marker for dementia in Parkinson’s disease. However, the motor domain offered a more nuanced picture. Among Parkinson’s disease patients carrying GBA1 mutations, higher TIMP2 levels were linked to increased postural instability, one of the axial motor features most closely associated with disease progression and falling risk. This connection is biologically plausible: postural instability reflects widespread brainstem and cortical involvement, processes in which extracellular matrix remodelling and neuroinflammatory cascades are deeply implicated.

The genetic analyses, though explicitly exploratory, may prove to be the study’s most provocative contribution. Specific variants within the TIMP2 gene, notably the single nucleotide polymorphisms rs1384364 and rs8068674, were associated with more favourable cognitive outcomes or delayed motor progression. In the key summary points accompanying the paper, the authors report that male patients with particular TIMP2 SNP genotypes exhibited delayed onset of cognitive impairment, higher scores on the Montreal Cognitive Assessment, or later onset of postural instability. If these findings replicate, they would suggest that inherited differences in how the extracellular matrix remodelling system is tuned help explain the notorious clinical heterogeneity of Parkinson’s disease, in which some patients remain cognitively intact for decades while others decline rapidly.

Taken together, the study’s central conclusion is one of careful reattribution. Rather than functioning as a disease-specific biomarker of Parkinson’s disease, cerebrospinal fluid TIMP2 appears to primarily reflect ageing-related processes intertwined with neurodegeneration. This distinction matters for how biomarkers are interpreted in clinical trials. Drugs targeting alpha-synuclein or GBA1, for example, would be poorly served by a surrogate endpoint that fluctuates mainly with chronological age. Conversely, if interventions designed to slow brain ageing or restore youthful extracellular matrix dynamics are to be developed, TIMP2 could serve as a pharmacodynamic readout of whether such strategies are engaging their intended biology. The authors suggest that TIMP2 quantification and its associated genetic variants show promise as biomarkers of pathological ageing, potentially informing therapeutic strategies for neurodegenerative diseases more broadly.

Several caveats frame the results. The control group was small, the genetic associations were exploratory and require replication in independent and larger cohorts, and cerebrospinal fluid sampling, while informative, is an invasive procedure that limits population-scale deployment. The interplay between TIMP2 in cerebrospinal fluid and its activity within brain parenchyma also remains to be fully mapped, as do the mechanistic consequences of the associated variants on protein expression or function. Nonetheless, by bridging a protein celebrated for rejuvenating aged mouse brains with the clinical realities of hundreds of Parkinson’s disease and dementia with Lewy bodies patients, the Tübingen team has supplied concrete human evidence that extracellular matrix-related ageing mechanisms are woven into the fabric of neurodegeneration. In doing so, the study adds momentum to a growing research movement that views Parkinson’s disease not simply as a disorder of misfolded proteins, but as a condition in which the ageing environment of the brain, its scaffolding, its plasticity reserves and its remodelling enzymes, determines how the disease ultimately expresses itself.

Subject of Research: TIMP2 cerebrospinal fluid levels and genetic variants as biomarkers of ageing and neurodegeneration in Parkinson's disease

Article Title: Exploring TIMP2 genetics and CSF levels in Parkinson’s disease: biomarkers of neurodegeneration and ageing

Article References: Zimmermann, M., Fandrich, M., Schulte, C., Jakobi, M., Wurster, I., Lerche, S., Zimmermann, S., Deuschle, C., Schneiderhan-Marra, N., Joos, T. O., Gasser, T., Brockmann, K., & Roeben, B. (2026). Exploring TIMP2 genetics and CSF levels in Parkinson’s disease: biomarkers of neurodegeneration and ageing. GeroScience. https://doi.org/10.1007/s11357-026-02495-2

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02495-2

Keywords: TIMP2, Parkinson's disease, dementia with Lewy bodies, cerebrospinal fluid biomarkers, matrix metalloproteinases, extracellular matrix, GBA1, neurodegeneration, ageing, cognitive impairment, postural instability, GeroScience